glp-1 employer coverage news october 2025 Medicare Drug Massachusetts cuts GLP-1 coverage for

The Danish study compared 2 mg weekly doses of exenatide (Byetta, AstraZeneca) with placebo and cognitive behavioral therapy as a control for smoking status at 6 and 12 months based on self-reported data

The science of transdermal patches: what works and what doesn't Why "GLP-1 patches" is misleading Inside the patch: an ingredient-by-ingredient look What real customers actually say Cost: are Kind Patches good value

These medications were originally developed to help manage type 2 diabetes, but they also support weight loss by slowing stomach emptying, stabilizing blood sugar levels, and increasing feelings of fullness and satisfaction, which can reduce appetite

Ongoing clinical trials are planned, including evaluating tirzepatide as adjunctive therapy in individuals with a BMI over 27 who are already receiving infliximab or adalimumab treatment (NCT06774079)

doi:10.1016/j.oret.2024.05.003 24